Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
The efficiency of heat treatment procedures of factor VIII and factor IX concentrates, prepared from voluntary, non-paid donors by three French Blood Transfusion Centres, on the inactivation of HIV and non-A, non-B hepatitis (NANB) viruses was assessed. Some 43 patients (26 haemophilia A, 17 haemophilia B) were followed for at least 1 year by testing for HIV antibodies and alanine aminotransferase (ALT). No HIV seroconversion was observed indicating that heat treatment was completely efficient. Among 26 haemophiliacs, 6 (4 haemophilia A, 2 haemophilia B) presented an elevation in ALT, indicating only a 75% reduction of NANB viral contamination.
D000163:Acquired Immunodeficiency Syndrome / Q000635:transmission; D000410:Alanine Transaminase / Q000097:blood; D001803:Blood Transfusion; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000628:therapy*; D002836:Hemophilia B / Q000628:therapy*; D006526:Hepatitis C / Q000635:transmission; D006358:Hot Temperature; D006801:Humans
D005169:Factor VIII; D005164:Factor IX; D000410:Alanine Transaminase